Tapewire

Nasdaq · USD

CTNM

Contineum Therapeutics, Inc.

Export transactions ↓
Tapewire entity
5311
SEC CIK
0001855175
Parsed reports
78

Last 12 months

Inside the activity.

0 purchase rows · 31 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202502
Jan 202604
Feb 202609
Mar 202602
Apr 202601
May 202602
Jun 202604
Jul 202605
Aug 202601
Sep 202601
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 08, 2026 Filed Sep 8, 2026 22:08 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 2,500 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · derivative · entry 3

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274,430

Underlying: Class A Common Stock · 2,500 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Read SEC document
September 08, 2026 Filed Sep 8, 2026 22:08 UTC
Stengone Carmine N.Director · CEO and President
SaleClass A Common Stock 2,500 $16.46 $41,141.50
Disclosure

SEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · nonDerivative · entry 2

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,217

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
September 08, 2026 Filed Sep 8, 2026 22:08 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 2,500 $1.01 $2,525.00
Disclosure

SEC source: 0001628280-26-060962 · wk-form4_1788905328.xml · nonDerivative · entry 1

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 22:14 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 2,500 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · derivative · entry 3

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 276,930

Underlying: Class A Common Stock · 2,500 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 22:14 UTC
Stengone Carmine N.Director · CEO and President
SaleClass A Common Stock 2,500 $16.01 $40,029.00
Disclosure

SEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · nonDerivative · entry 2

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,217

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 22:14 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 2,500 $1.01 $2,525.00
Disclosure

SEC source: 0001628280-26-052031 · wk-form4_1785795270.xml · nonDerivative · entry 1

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 09, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionStock Option (right to buy) · Derivative 25 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · derivative · entry 7

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,257

Underlying: Class A Common Stock · 25 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
July 09, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 25 $16.00 $400.00
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 4

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,202

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 09, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionClass A Common Stock 25 $1.01 $25.25
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 3

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 08, 2026 Filed Jul 8, 2026 22:49 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 2,500 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · derivative · entry 3

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 279,430

Underlying: Class A Common Stock · 2,500 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Read SEC document
July 08, 2026 Filed Jul 8, 2026 22:49 UTC
Stengone Carmine N.Director · CEO and President
SaleClass A Common Stock 2,500 $16.00 $40,000.00
Disclosure

SEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · nonDerivative · entry 2

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,217

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 08, 2026 Filed Jul 8, 2026 22:49 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 2,500 $1.01 $2,525.00
Disclosure

SEC source: 0001628280-26-047710 · wk-form4_1783550956.xml · nonDerivative · entry 1

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionStock Option (right to buy) · Derivative 1,015 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · derivative · entry 6

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,282

Underlying: Class A Common Stock · 1,015 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 1,015 $16.00 $16,240.00
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 2

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,202

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 08, 2026 Filed Jul 10, 2026 21:20 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionClass A Common Stock 1,015 $1.01 $1,025.15
Disclosure

SEC source: 0001628280-26-047909 · wk-form4_1783718438.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionStock Option (right to buy) · Derivative 4,183 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · derivative · entry 8

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,297

Underlying: Class A Common Stock · 4,183 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F6 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 2,501 $16.24 $40,608.49
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 5

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,202

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 5,852 $15.67 $91,681.53
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 4

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,703

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionClass A Common Stock 4,183 $1.01 $4,224.83
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 3

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Watkins TimCMO & Head of Development
Exercise / conversionStock Option (right to buy) · Derivative 10,833 $0.00 Strike: $4.50 $0.00
Disclosure

SEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · derivative · entry 3

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,334

Underlying: Class A Common Stock · 10,833 shares

Expires 2035-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Watkins TimCMO & Head of Development
SaleClass A Common Stock 10,833 $16.02 $173,590.16
Disclosure

SEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · nonDerivative · entry 2

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,961

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Watkins TimCMO & Head of Development
Exercise / conversionClass A Common Stock 10,833 $4.50 $48,748.50
Disclosure

SEC source: 0001628280-26-046654 · wk-form4_1782947093.xml · nonDerivative · entry 1

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 2,500 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · derivative · entry 5

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,417

Underlying: Class A Common Stock · 2,500 shares

Expires 2028-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 7,500 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · derivative · entry 4

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 281,930

Underlying: Class A Common Stock · 7,500 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · derivative.exercise_date: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Stengone Carmine N.Director · CEO and President
SaleClass A Common Stock 10,000 $16.01 $160,080.00
Disclosure

SEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 3

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,217

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 2,500 $1.26 $3,150.00
Disclosure

SEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 2

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
June 30, 2026 Filed Jul 1, 2026 23:04 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 7,500 $1.01 $7,575.00
Disclosure

SEC source: 0001628280-26-046653 · wk-form4_1782947042.xml · nonDerivative · entry 1

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
June 30, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionStock Option (right to buy) · Derivative 28,826 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · derivative · entry 7

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,480

Underlying: Class A Common Stock · 28,826 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F6 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
June 30, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 28,826 $16.04 $462,288.33
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 2

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,372

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 30, 2026 Filed Jul 2, 2026 21:47 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionClass A Common Stock 28,826 $1.01 $29,114.26
Disclosure

SEC source: 0001628280-26-047058 · wk-form4_1783028831.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,198

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:45 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045843 · wk-form4_1782510325.xml · derivative · entry 1

Lyons-Williams Lori · CIK 0001693564 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:46 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045845 · wk-form4_1782510384.xml · derivative · entry 1

Miralles Gines Diego · CIK 0001773413 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:44 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045841 · wk-form4_1782510295.xml · derivative · entry 1

Ware Olivia C · CIK 0001663771 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:44 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045839 · wk-form4_1782510265.xml · derivative · entry 1

Schimmelpennink Evert B. · CIK 0001713795 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:43 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045837 · wk-form4_1782510226.xml · derivative · entry 1

Ignelzi Troy A. · CIK 0001579829 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:42 UTC
Boyce SarahDirector
GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045833 · wk-form4_1782510140.xml · derivative · entry 1

Boyce Sarah · CIK 0001629383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 26, 2026 Filed Jun 26, 2026 21:43 UTC GrantStock Option (right to buy) · Derivative 19,000 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001628280-26-045835 · wk-form4_1782510189.xml · derivative · entry 1

Brady Todd R. · CIK 0001767644 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Stock · 19,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Read SEC document
June 01, 2026 Filed Jun 1, 2026 22:08 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 4,170 $13.16 $54,862.19
Disclosure

SEC source: 0001628280-26-039641 · wk-form4_1780351717.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,372

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995 to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
May 01, 2026 Filed May 1, 2026 21:42 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 300 $13.84 $4,152.00
Disclosure

SEC source: 0001628280-26-029435 · wk-form4_1777671753.xml · nonDerivative · entry 2

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,542

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
May 01, 2026 Filed May 1, 2026 21:42 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 3,870 $13.06 $50,542.20
Disclosure

SEC source: 0001628280-26-029435 · wk-form4_1777671753.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,842

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
April 06, 2026 Filed Apr 6, 2026 21:43 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 4,170 $13.43 $56,013.94
Disclosure

SEC source: 0001628280-26-023949 · wk-form4_1775511809.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,712

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
March 02, 2026 Filed Mar 2, 2026 23:28 UTC
Watkins TimCMO & Head of Development
Exercise / conversionStock Option (right to buy) · Derivative 3,611 $0.00 Strike: $4.50 $0.00
Disclosure

SEC source: 0001437749-26-006421 · rdgdoc.xml · derivative · entry 3

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 249,167

Underlying: Class A Common Stock · 3,611 shares

Expires 2035-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · derivative.exercise_date: One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

Read SEC document
March 02, 2026 Filed Mar 2, 2026 23:28 UTC
Watkins TimCMO & Head of Development
SaleClass A Common Stock 3,611 $15.02 $54,220.25
Disclosure

SEC source: 0001437749-26-006421 · rdgdoc.xml · nonDerivative · entry 2

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
March 02, 2026 Filed Mar 2, 2026 23:28 UTC
Watkins TimCMO & Head of Development
Exercise / conversionClass A Common Stock 3,611 $4.50 $16,249.50
Disclosure

SEC source: 0001437749-26-006421 · rdgdoc.xml · nonDerivative · entry 1

Watkins Tim · CIK 0002065965 · CMO & Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
March 02, 2026 Filed Mar 2, 2026 23:30 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 4,170 $15.01 $62,585.03
Disclosure

SEC source: 0001437749-26-006422 · rdgdoc.xml · nonDerivative · entry 1

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,882

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
February 25, 2026 Filed Feb 26, 2026 21:40 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionStock Option (right to buy) · Derivative 2,700 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001437749-26-005892 · rdgdoc.xml · derivative · entry 6

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,917

Underlying: Class A Common Stock · 2,700 shares

Expires 2028-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
February 25, 2026 Filed Feb 26, 2026 21:40 UTC
Stengone Carmine N.Director · CEO and President
SaleClass A Common Stock 2,700 $16.02 $43,241.85
Disclosure

SEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 4

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,954

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
February 25, 2026 Filed Feb 26, 2026 21:40 UTC
Stengone Carmine N.Director · CEO and President
Exercise / conversionClass A Common Stock 2,700 $1.26 $3,402.00
Disclosure

SEC source: 0001437749-26-005892 · rdgdoc.xml · nonDerivative · entry 3

Stengone Carmine N. · CIK 0001861519 · Director · CEO and President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

Read SEC document
February 25, 2026 Filed Feb 26, 2026 21:39 UTC
Lorrain Daniel S.Chief Scientific Officer
Exercise / conversionStock Option (right to buy) · Derivative 3,824 $0.00 Strike: $1.01 $0.00
Disclosure

SEC source: 0001437749-26-005889 · rdgdoc.xml · derivative · entry 7

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,306

Underlying: Class A Common Stock · 3,824 shares

Expires 2030-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F4 · derivative.exercise_date: The stock options are fully vested and exercisable.

Read SEC document
February 25, 2026 Filed Feb 26, 2026 21:39 UTC
Lorrain Daniel S.Chief Scientific Officer
SaleClass A Common Stock 3,824 $16.01 $61,227.98
Disclosure

SEC source: 0001437749-26-005889 · rdgdoc.xml · nonDerivative · entry 4

Lorrain Daniel S. · CIK 0001861550 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,052

F1 · kind: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.